Evaluation of Extracellular Matrix Composition to Improve Breast Cancer Modeling.

ABSTRACT: The development of resistance to therapy is a significant obstacle to effective therapeutic regimens. Evaluating the effects of oncology drugs in the laboratory setting is limited by the lack of translational models that accurately recapitulate cell-microenvironment interactions present in tumors. Acquisition of resistance to therapy is facilitated, in part, by the composition of the tumor extracellular matrix (ECM), with the primary current in vitro model using collagen I (COL I). Here we seek to identify the prevalence of COL I-enhanced expression in the triple-negative breast cancer (TNBC) subtype. Furthermore, we identify if methods of response to therapy are altered depending on matrix composition. We demonstrated that collagen content varies in patient tumor samples across sub

SUBMITTER: Byrne CE 

PROVIDER: S-EPMC8349725 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature